Tandem Diabetes Care (NASDAQ:TNDM) Price Target Raised to $36.00

Tandem Diabetes Care (NASDAQ:TNDM) had its target price increased by Robert W. Baird from $28.00 to $36.00 in a report issued on Friday morning, Benzinga reports. They currently have a neutral rating on the medical device company’s stock.

Several other brokerages have also issued reports on TNDM. Leerink Partnrs upgraded Tandem Diabetes Care from a market perform rating to an outperform rating in a report on Thursday, April 25th. Wells Fargo & Company raised shares of Tandem Diabetes Care from an equal weight rating to an overweight rating and lifted their price target for the company from $21.00 to $45.00 in a research report on Monday, April 29th. Stifel Nicolaus boosted their price target on shares of Tandem Diabetes Care from $37.00 to $40.00 and gave the company a buy rating in a research note on Tuesday, April 23rd. StockNews.com raised shares of Tandem Diabetes Care from a sell rating to a hold rating in a research note on Friday, April 19th. Finally, SVB Leerink raised shares of Tandem Diabetes Care from a market perform rating to an outperform rating and boosted their target price for the stock from $34.00 to $45.00 in a research report on Thursday, April 25th. Three research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat.com, Tandem Diabetes Care presently has an average rating of Moderate Buy and a consensus target price of $43.80.

Tandem Diabetes Care Trading Down 2.7 %

NASDAQ:TNDM opened at $43.50 on Friday. The company has a current ratio of 3.81, a quick ratio of 3.01 and a debt-to-equity ratio of 1.43. Tandem Diabetes Care has a twelve month low of $13.82 and a twelve month high of $47.00. The company has a fifty day moving average of $32.58 and a 200-day moving average of $26.35.

Tandem Diabetes Care (NASDAQ:TNDM) last posted its quarterly earnings results on Wednesday, February 21st. The medical device company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($0.04). Tandem Diabetes Care had a negative net margin of 18.37% and a negative return on equity of 34.38%. The company had revenue of $196.80 million during the quarter, compared to the consensus estimate of $204.86 million. On average, analysts predict that Tandem Diabetes Care will post -1.62 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Tandem Diabetes Care

Institutional investors have recently modified their holdings of the business. MCF Advisors LLC grew its stake in Tandem Diabetes Care by 79.3% in the 1st quarter. MCF Advisors LLC now owns 1,006 shares of the medical device company’s stock valued at $36,000 after purchasing an additional 445 shares during the period. Van ECK Associates Corp grew its position in Tandem Diabetes Care by 8.6% during the fourth quarter. Van ECK Associates Corp now owns 5,900 shares of the medical device company’s stock valued at $175,000 after buying an additional 467 shares during the period. Diversified Trust Co increased its holdings in Tandem Diabetes Care by 5.6% during the fourth quarter. Diversified Trust Co now owns 10,573 shares of the medical device company’s stock worth $313,000 after buying an additional 564 shares during the last quarter. Raymond James & Associates raised its position in Tandem Diabetes Care by 1.9% in the third quarter. Raymond James & Associates now owns 40,264 shares of the medical device company’s stock worth $836,000 after acquiring an additional 737 shares during the period. Finally, Commonwealth Equity Services LLC boosted its stake in Tandem Diabetes Care by 10.1% in the third quarter. Commonwealth Equity Services LLC now owns 9,870 shares of the medical device company’s stock valued at $205,000 after acquiring an additional 908 shares during the last quarter.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.